Bristol-Myers Squibb reports Q2 earnings on July 30 with the stock at $63.60 and options traders notably relaxed — yet short interest has just posted its sharpest weekly jump in months, creating a quiet tension under an otherwise constructive surface.
The short interest story is the week's most notable shift. Shorts have rebuilt aggressively: SI as a percentage of the free float rose roughly 31% over the past week, climbing from around 1.9% to 2.4%. In absolute terms, borrowed shares jumped from approximately 37.3 million on July 21 to nearly 49.6 million by July 28 — the highest level in the 30-day window. That's a meaningful acceleration, even if the absolute level remains modest. Borrow conditions don't suggest a squeeze is building. Availability is extremely loose at over 5,700% of short interest — meaning for every share currently borrowed, there are roughly 57 available in the lending pool. Cost to borrow has actually eased over the week, down 36% to around 0.38%. The lending market is wide open; the rebuilding of shorts is a directional bet, not a forced trade.
Options positioning pulls in the opposite direction and tells a more constructive story. The put/call ratio has dropped to 0.82, now running about 1.6 standard deviations below its 20-day average of 0.87. That's one of the most call-skewed readings of the past year, sitting close to the 52-week low of 0.72. Options traders are leaning into the upside heading into earnings, not hedging away from it. The contrast with the short interest rebuild is striking: two sets of market participants appear to be making opposing bets on the same catalyst.
The Street broadly supports the bull case, though with diminishing conviction at current prices. The mean analyst price target of $62.96 now sits fractionally below the current price of $63.60 — a reversal from a week ago, when the stock was trading at $62.09 and the target offered a small cushion. B of A Securities trimmed its target to $66 from $67 on July 10 while keeping a Buy, and Cantor Fitzgerald held its Neutral at $54. Guggenheim holds at $72 Overweight and Piper Sandler at $75 Overweight; those bulls see meaningful upside from here. The bears cluster around $54–$60, focused on competition in rare cardiovascular and oncology markets, genericization pressure on Revlimid, and regulatory risk in the pipeline. EV/EBITDA is running at 9.5x, up modestly over the past month, and the P/E of 10.2x reflects a stock that remains cheap relative to larger-cap pharma peers — MRK and JNJ both put on roughly 4–6% this week, broadly in line with BMY's 4.4% weekly gain, suggesting the sector tailwind is real. The ORTEX dividend score ranks in the 99th percentile, reflecting an unusually strong yield profile for investors running income-oriented positions.
Earnings reaction history offers limited guidance. The prior print in early May produced a 1.4% single-day decline, with the stock drifting a further half-percent lower over five days. The April print initially lifted the stock 1.1% on day one before fading 2.3% by day five. The pattern is modest moves in either direction, with a slight tilt toward near-term softness after the initial reaction — but neither print was large enough to define the range for July 30.
The key thing to watch on Wednesday is whether management's commentary on Growth Product revenue trajectory and the Revlimid offset is strong enough to justify a stock that has now moved past its consensus target — because with SI having jumped 31% in a week, any disappointment arrives into a freshly rebuilt short position.
See the live data behind this article on ORTEX.
Open BMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
